Website: promab.com   |   LinkedIn: linkedin.com/company/promab-biotechnologies-inc.

From Antibody to CAR-T, Under One Roof

How ProMab Biotechnologies turned two decades of antibody expertise into a turnkey platform for immunotherapy research

At a glance

  • Company: ProMab Biotechnologies (promab.com)
  • Founded: 2001, Richmond, California, about 15 minutes from San Francisco
  • Focus: Antibodies, recombinant proteins, engineered cell lines, primary cells, CAR-T/CAR-NK cells, and mRNA-LNP products and services
  • Working with PSG on: HubSpot implementation

Antibody experts first

ProMab started where great immunotherapies start: with the antibody. For more than 20 years, the company has developed mouse, rabbit, and human monoclonal antibodies, along with hybridomas, recombinant proteins, and engineered cell lines for researchers worldwide.

That foundation gives ProMab a real edge in cell therapy. Because it understands the binder, it can design, humanize, and optimize the targeting domain that makes a CAR-T or CAR-NK cell work.

A turnkey CAR-T platform

ProMab built a complete CAR-T workflow, from antibody and hybridoma screening through lentivirus production, mRNA transfection, CAR-T generation, and functional testing.

  • 3,000+ CAR-T constructs designed and tested, with reliable measurements of CAR expression, cytokine release, and cytotoxicity
  • Antibody humanization and affinity tuning of scFvs, then testing them in CAR-T/NK settings in vitro and in vivo
  • Bispecific antibodies and bispecific CARs
  • Scale-up: CAR-T manufacturing at 1 billion cells or more using WAVE and G-Rex bioreactors
  • mRNA-LNP services that add a new delivery modality to antibody and cell engineering

ProMab’s science has moved beyond the bench. Its humanized CD19 CAR-T cells were evaluated in an investigator-initiated clinical study in relapsed and refractory blood cancers.

Products and services, individually or together

Researchers can buy off-the-shelf antibodies, proteins, CAR-T/NK cells, cell lines, primary cells, and media, or combine custom antibody engineering, cell line engineering, CAR-T/NK, and protein expression services into one tailored package.